Use of catechol-O-methyl transferase (COMT) inhibitors and their physiologically acceptable salts for ulcer treatment

US5001152A · kind A · utility

Assignee

• ORION CORPORATION · FI

Inventors

• Paivi A. Aho · Helsinki, FI
• Pentti Pohto · Helsinki, FI
• Inge-Britt Y. Linden · Espoo, FI
• Reijo Backstrom · Helsinki, FI
• Erkki J. Honkanen · Vantaa, FI
• Erkki A. O. Nissenen · Espoo, FI

Key dates

• Filing date: Dec 23, 1988
• Grant date: Mar 19, 1991
• Expiry date: Dec 23, 2008

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P1/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention is concerned with the new use of known catechol derivatives of the formula ##STR1## wherein R.sub.1 and R.sub.2 are each hydrogen, alkyl having 1 to 4 carbon atoms or alkanoyl having 2 to 5 carbon atoms; X is nitro, halogen or cyano and R.sub.3 is chlorine, nitro, cyano or a radical of the formula ##STR2## wherein R.sub.4 is hydrogen, cyano, alkyl having 1 to 4 carbon atoms or alkanoyl having 2 to 5 carbon atoms and R.sub.5 is cyano, alkanoyl having 2 to 5 carbon atoms, hydroxyalkyl having 1 to 4 carbon atoms, carboxyl or phenylcarbonyl unsubstituted or substituted with one to three methoxy groups or pharmaceutically acceptable salt thereof. The new use is the treatment and prophylaxis of ulcers and lesions in the gastrointestinal tract.